Research programme: inflammation therapy - Millennium/MorphoSys
Alternative Names: Inflammation therapy research programme - Millennium/MorphoSysLatest Information Update: 01 Aug 2024
At a glance
- Originator Millennium Pharmaceuticals; MorphoSys
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 24 May 2002 Discontinued - Preclinical for Inflammation in Germany (unspecified route)
- 24 May 2002 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 17 Jul 2001 New profile